Concepts (187)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 22 | 2024 | 391 | 6.530 |
Why?
|
| Cell-Free Nucleic Acids | 4 | 2024 | 83 | 3.010 |
Why?
|
| Neoplasms, Second Primary | 5 | 2023 | 240 | 2.370 |
Why?
|
| 5-Methylcytosine | 3 | 2024 | 117 | 1.630 |
Why?
|
| Sarcoma, Ewing | 4 | 2014 | 42 | 1.610 |
Why?
|
| Bone Neoplasms | 6 | 2023 | 321 | 1.500 |
Why?
|
| Osteosarcoma | 2 | 2023 | 163 | 0.980 |
Why?
|
| Child | 18 | 2024 | 7216 | 0.930 |
Why?
|
| Child, Preschool | 15 | 2024 | 3765 | 0.890 |
Why?
|
| Prognosis | 12 | 2024 | 3810 | 0.880 |
Why?
|
| Biomarkers, Tumor | 6 | 2024 | 1550 | 0.870 |
Why?
|
| Infant | 13 | 2024 | 3183 | 0.790 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2021 | 20 | 0.780 |
Why?
|
| Pediatrics | 3 | 2021 | 361 | 0.730 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 36 | 0.670 |
Why?
|
| Oncologists | 1 | 2019 | 39 | 0.650 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2024 | 1286 | 0.640 |
Why?
|
| Machine Learning | 1 | 2021 | 271 | 0.640 |
Why?
|
| Epigenomics | 1 | 2019 | 103 | 0.640 |
Why?
|
| Fathers | 1 | 2019 | 72 | 0.630 |
Why?
|
| Inflammation | 1 | 2024 | 990 | 0.620 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 338 | 0.600 |
Why?
|
| Neoplasms | 6 | 2024 | 3029 | 0.600 |
Why?
|
| T-Lymphocytes | 1 | 2024 | 1228 | 0.590 |
Why?
|
| Humans | 40 | 2024 | 90568 | 0.540 |
Why?
|
| Survivors | 2 | 2016 | 191 | 0.530 |
Why?
|
| Adolescent | 13 | 2022 | 9353 | 0.520 |
Why?
|
| DNA Methylation | 2 | 2022 | 666 | 0.510 |
Why?
|
| Young Adult | 11 | 2022 | 6425 | 0.450 |
Why?
|
| Hypoxia | 3 | 2023 | 660 | 0.450 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2011 | 129 | 0.430 |
Why?
|
| Radiation Injuries | 1 | 2014 | 159 | 0.430 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 207 | 0.430 |
Why?
|
| Transition to Adult Care | 1 | 2013 | 23 | 0.410 |
Why?
|
| Rheumatic Diseases | 1 | 2013 | 26 | 0.410 |
Why?
|
| Annexin A5 | 1 | 2012 | 20 | 0.410 |
Why?
|
| Radiotherapy | 1 | 2014 | 318 | 0.410 |
Why?
|
| Medical Informatics | 1 | 2013 | 50 | 0.400 |
Why?
|
| Genomics | 2 | 2022 | 784 | 0.400 |
Why?
|
| Methyltransferases | 2 | 2024 | 193 | 0.400 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2011 | 6 | 0.390 |
Why?
|
| Patient Preference | 1 | 2013 | 117 | 0.380 |
Why?
|
| Male | 16 | 2024 | 42931 | 0.380 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 538 | 0.360 |
Why?
|
| Female | 19 | 2024 | 46855 | 0.360 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 802 | 0.350 |
Why?
|
| N-Myc Proto-Oncogene Protein | 2 | 2022 | 39 | 0.350 |
Why?
|
| Apoptosis | 3 | 2023 | 1723 | 0.350 |
Why?
|
| Aging | 1 | 2014 | 727 | 0.320 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2016 | 854 | 0.300 |
Why?
|
| Models, Biological | 2 | 2016 | 1770 | 0.300 |
Why?
|
| Cell Line, Tumor | 7 | 2024 | 2607 | 0.280 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 842 | 0.270 |
Why?
|
| Adult | 10 | 2022 | 26940 | 0.260 |
Why?
|
| Paraffin Embedding | 2 | 2016 | 78 | 0.250 |
Why?
|
| Infant, Newborn | 5 | 2022 | 2501 | 0.240 |
Why?
|
| Medical Oncology | 2 | 2021 | 381 | 0.240 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2024 | 44 | 0.230 |
Why?
|
| Risk Factors | 4 | 2021 | 5580 | 0.230 |
Why?
|
| Disease-Free Survival | 3 | 2022 | 1170 | 0.220 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2024 | 174 | 0.220 |
Why?
|
| Signal Transduction | 1 | 2014 | 3426 | 0.220 |
Why?
|
| Cohort Studies | 3 | 2021 | 2893 | 0.210 |
Why?
|
| Induction Chemotherapy | 2 | 2022 | 153 | 0.210 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2023 | 23 | 0.210 |
Why?
|
| Teratoma | 1 | 2023 | 52 | 0.210 |
Why?
|
| SEER Program | 2 | 2014 | 201 | 0.210 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2023 | 49 | 0.200 |
Why?
|
| DNA, Neoplasm | 1 | 2023 | 266 | 0.200 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2023 | 105 | 0.200 |
Why?
|
| Mixed Function Oxygenases | 1 | 2022 | 69 | 0.200 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2022 | 43 | 0.200 |
Why?
|
| High-Intensity Focused Ultrasound Ablation | 1 | 2023 | 46 | 0.200 |
Why?
|
| Cell Proliferation | 3 | 2024 | 1688 | 0.190 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2023 | 493 | 0.190 |
Why?
|
| Gene Amplification | 2 | 2023 | 135 | 0.190 |
Why?
|
| Survival Rate | 3 | 2020 | 1899 | 0.190 |
Why?
|
| Research Report | 1 | 2021 | 43 | 0.190 |
Why?
|
| Histones | 1 | 2024 | 344 | 0.190 |
Why?
|
| Radionuclide Imaging | 1 | 2021 | 222 | 0.190 |
Why?
|
| Incidence | 2 | 2016 | 1594 | 0.190 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 103 | 0.180 |
Why?
|
| Research Subjects | 1 | 2021 | 73 | 0.180 |
Why?
|
| Transforming Growth Factor beta | 1 | 2023 | 326 | 0.180 |
Why?
|
| Glioma | 1 | 2023 | 295 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2021 | 2364 | 0.180 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2020 | 59 | 0.180 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 1708 | 0.170 |
Why?
|
| Parenchymal Tissue | 1 | 2020 | 6 | 0.170 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 2018 | 0.170 |
Why?
|
| Intergenerational Relations | 1 | 2019 | 5 | 0.170 |
Why?
|
| Bayes Theorem | 1 | 2021 | 385 | 0.170 |
Why?
|
| Pleura | 1 | 2020 | 32 | 0.170 |
Why?
|
| Back Pain | 1 | 2019 | 43 | 0.170 |
Why?
|
| Family Relations | 1 | 2019 | 36 | 0.170 |
Why?
|
| Age Factors | 2 | 2021 | 1871 | 0.170 |
Why?
|
| Naphthyridines | 1 | 2019 | 27 | 0.160 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2022 | 665 | 0.160 |
Why?
|
| Survival Analysis | 1 | 2021 | 1499 | 0.140 |
Why?
|
| Cell Differentiation | 1 | 2024 | 1547 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 1357 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 2523 | 0.140 |
Why?
|
| Serum Albumin, Bovine | 1 | 2016 | 45 | 0.140 |
Why?
|
| Osteonectin | 1 | 2016 | 22 | 0.140 |
Why?
|
| Palmitic Acid | 1 | 2016 | 29 | 0.140 |
Why?
|
| Databases, Nucleic Acid | 1 | 2016 | 41 | 0.140 |
Why?
|
| Ovarian Neoplasms | 1 | 2023 | 776 | 0.130 |
Why?
|
| Retrospective Studies | 3 | 2023 | 9323 | 0.130 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2020 | 269 | 0.130 |
Why?
|
| Tissue Fixation | 1 | 2016 | 40 | 0.130 |
Why?
|
| Formaldehyde | 1 | 2016 | 52 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 846 | 0.130 |
Why?
|
| Lipid Metabolism | 1 | 2016 | 202 | 0.120 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 1066 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 914 | 0.120 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 294 | 0.120 |
Why?
|
| DNA Repair | 1 | 2016 | 363 | 0.120 |
Why?
|
| Mass Spectrometry | 1 | 2014 | 196 | 0.110 |
Why?
|
| Treatment Outcome | 4 | 2022 | 8373 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 693 | 0.110 |
Why?
|
| Radiation Dosage | 1 | 2014 | 230 | 0.110 |
Why?
|
| Computational Biology | 1 | 2016 | 552 | 0.110 |
Why?
|
| Reference Values | 1 | 2014 | 662 | 0.110 |
Why?
|
| Consumer Health Information | 1 | 2013 | 15 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2016 | 2335 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 3692 | 0.100 |
Why?
|
| Focus Groups | 1 | 2013 | 179 | 0.100 |
Why?
|
| Self Care | 1 | 2013 | 166 | 0.090 |
Why?
|
| Transcriptome | 1 | 2016 | 668 | 0.090 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2011 | 9 | 0.090 |
Why?
|
| Sex Factors | 1 | 2014 | 1074 | 0.090 |
Why?
|
| Qualitative Research | 1 | 2013 | 312 | 0.090 |
Why?
|
| Mice | 5 | 2024 | 11932 | 0.090 |
Why?
|
| Social Support | 1 | 2013 | 219 | 0.090 |
Why?
|
| Heterografts | 2 | 2023 | 105 | 0.090 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 1460 | 0.090 |
Why?
|
| Patient Participation | 1 | 2013 | 227 | 0.090 |
Why?
|
| Disease Management | 1 | 2013 | 332 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 2782 | 0.090 |
Why?
|
| Lymphatic Metastasis | 1 | 2011 | 498 | 0.080 |
Why?
|
| Computer Simulation | 1 | 2014 | 1103 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2013 | 959 | 0.080 |
Why?
|
| Bone and Bones | 1 | 2011 | 273 | 0.080 |
Why?
|
| Cell Hypoxia | 2 | 2022 | 172 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2014 | 2892 | 0.080 |
Why?
|
| International Cooperation | 2 | 2020 | 126 | 0.070 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 1735 | 0.070 |
Why?
|
| Cell Movement | 2 | 2022 | 793 | 0.060 |
Why?
|
| Animals | 5 | 2024 | 27691 | 0.060 |
Why?
|
| Ubiquitination | 1 | 2024 | 75 | 0.060 |
Why?
|
| Proteolysis | 1 | 2024 | 118 | 0.060 |
Why?
|
| Middle Aged | 2 | 2014 | 26327 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2022 | 4345 | 0.050 |
Why?
|
| HeLa Cells | 1 | 2023 | 520 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 6812 | 0.050 |
Why?
|
| Adenosine | 1 | 2024 | 242 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 185 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 351 | 0.050 |
Why?
|
| Mice, Nude | 1 | 2023 | 819 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 407 | 0.050 |
Why?
|
| Mitotic Index | 1 | 2020 | 22 | 0.040 |
Why?
|
| Mitosis | 1 | 2020 | 152 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2022 | 281 | 0.040 |
Why?
|
| Cough | 1 | 2020 | 55 | 0.040 |
Why?
|
| Dyspnea | 1 | 2020 | 76 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 705 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2024 | 703 | 0.040 |
Why?
|
| Fibrosis | 1 | 2020 | 238 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2020 | 377 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2024 | 3273 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2021 | 413 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 70 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 692 | 0.030 |
Why?
|
| Diffusion of Innovation | 1 | 2015 | 74 | 0.030 |
Why?
|
| Aged | 1 | 2012 | 19404 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 130 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 319 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2016 | 384 | 0.030 |
Why?
|
| Cell Survival | 1 | 2016 | 987 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 180 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2016 | 373 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1873 | 0.030 |
Why?
|
| Mutation | 1 | 2023 | 4184 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 1741 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 1695 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 2424 | 0.020 |
Why?
|
| Time Factors | 1 | 2015 | 5365 | 0.020 |
Why?
|